Teva Pharmaceutical Industries Ltd.

Fourth Quarter and Full Year 2022 Results

February 8, 2023

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and any delay in our ability to obtain sufficient participation of plaintiffs for the nationwide settlement of our opioid-related litigation in the United States; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice ("DOJ") criminal charges of Sherman Act violations; potential liability for Intellectual property right infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks and the impact of Environmental, Social and Governance ("ESG") issues;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the ongoing conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022 ("Annual Report"), including in the sections captioned "Risk Factors" and "Forward-looking statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our press release reporting our financial results for the fourth quarter of 2022 and the year ended December 31, 2022, as well as our Annual Report on Form 10-K for year ended December 31, 2022, for a reconciliation of the non-GAAP financial measures to their nearest GAAP equivalents. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva's management and board of directors, in conjunction with other performance metrics, to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management; the company's annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing forward looking guidance for GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

Some amounts in this presentation may not add up due to rounding. All percentages have been calculated using unrounded amounts.

Richard Francis

President and Chief Executive Officer

2022 Highlights

Financial

- Revenues of $14.9 billion
- Adjusted EBITDA of $4.6 billion
- GAAP diluted loss per share of $2.12; non-GAAP diluted EPS of $2.52
- Significant foreign exchange headwinds on revenues:
  - Q4 2022 net impact of $270 million*
  - FY 2022 net impact of $780 million**
- Free cash flow of $2,243 million
- Debt reduction continues; net debt reduced to $18.4 billion


Business

- **AUSTEDO®** – reached $971 million globally, up 20% in the U.S.
- **AJOVY®** – continued revenue growth in the U.S. and Europe
- **Generics** –
  - **Europe** revenues up 9% in local currency, reflecting higher demand and successful new product launches, including generic Eliquis®
  - **International Markets** revenues up 5% in local currency, reflecting market growth and inflation related price increases
- Initiated phase 3 trial of subcutaneous long-acting **Olanzapine** for Schizophrenia
- **U.S. nationwide opioid litigation settlement** - high level of state participation in the sign-on process

* Compared to Q4 2021
** Compared to FY 2021

Revenue Development


$ millions



Q1 2021 actual results include revenues from generic products in Japan divested on February 1, 2021, along with a manufacturing site

Spotlight on Our Business in Europe

Europe Revenues and Operating Margin* Development



Highlights


- Growing business with solid fundamentals
- High profitability
- Strong leadership position in all key markets
- Broad portfolio and pipeline
- Proven go-to-market model in generics, biosimilars, OTC and innovative products

* does not include amortization and certain other items

AUSTEDO®


Austedo® (deutetrabenazine)
6 mg, 9 mg, and 12 mg tablets

AUSTEDO TRx Count Per Quarter



Source: IQVIA US NPA Audit

AUSTEDO Revenues By Quarter ($ million)




Source: Company Information

Highlights

- U.S. sales:
  - $963 million in FY 2022, an increase of 20% vs. 2021
  - $344 million in Q4 2022, an increase of 22% vs. Q4 2021
- Prescription trends:
  - ~199K in 2022 vs. ~157K in 2021, up 27%
  - ~55K in Q4 2022 vs. ~43K in Q4 2021, up 28%;

teva

Tardive Dyskinesia - Widespread and Undertreated




Significant potential for long-term growth

Source: Cerner Enviza Patient TD and HD chorea Patient Analysis Sept 2022


AJOVY®

AJOVY® (fremanezumab-vfrm) injection 225 mg/1.5 mL

AJOVY U.S. QTR Normalized TRx



AJOVY EU Monthly Volume Market Share



Highlights

- Net global sales of $377 million in FY 2022 and $123 million in Q4 2022:
  - **North America** – $218 million in FY 2022 and $75 million in Q4 2022
  - **Europe** – $124 million in FY 2022 and $35 million in Q4 2022
  - **International Markets** – $35 million in FY 2022 and $13 million in Q4 2022

Source: IQVIA US NPA Audit

Teva Innovative Medicine & Biosimilar Pipeline

By development stage – as of February 1, 2023

Preclinical

- TEV-56278 Oncology
- TEV-56279 Neuroscience
- TEV-56288 Neuroscience
- TEV-48438 Schizophrenia
- TEV-56287[3] Parkinson's Disease
- TEV-46000 Neuroscience
- TEV-56285
- TEV-54142
- TEV-56191
- TEV-56261
- TEV-56284[1]
- TEV-56289

Phase 1

- TEV-53408 Gastrointestinal
- TEV-56286[3] Multiple System Atrophy
- Biosimilar to Simponi® (golimumab)[1]
- TEV-56192 Neuroscience
- TEV-56248 Respiratory

Phase 2

- TEV-48574 Inflammatory Bowel Disease

Phase 3

- Olanzapine LAI Schizophrenia
- Deutetrabenazine[2] Dyskinesia in Cerebral Palsy
- Biosimilar to Prolia® & Xgeva® (denosumab)
- Biosimilar to Xolair® (omalizumab)
- Biosimilar to Eylea® (aflibercept)[1]

Pre-Submission

- Digihaler® (beclomethasone dipropionate HFA) (US)

Under Regulatory Review

- Biosimilar to Humira® (adalimumab)[1]
- Risperidone LAI Schizophrenia
- Biosimilar to Stelara® (ustekinumab)[1]
- Digihaler® (budesonide and formoterol fumarate dihydrate) (EU)

Teva innovative medicine & biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
Pipeline is current as of February 1, 2023


1) In collaboration with Alvotech for the U.S. market.
2) This use is investigational.
3) In collaboration with MODAG.

TECHNOLOGY PLATFORMS


- Biosimilars
- Novel Biologics
- Small Molecules
- Digital Respiratory

Building a Schizophrenia Franchise

Schizophrenia Patients Population*



Atypical Antipsychotics Market 2022*



*Annual LAI Sales*** **~$4 billion***

UZEDY™: resubmitted NDA to the FDA in October 2022; anticipated action date in H1/23

- Desirable pharmacokinetics
- Simplified administration
- Ready to use

UZEDY™ (risperidone) extended-release injectable suspension

Initiated phase 3 trial of subcutaneous long-acting Olanzapine for Schizophrenia

* Source: DRG / Clarivate (2022)
** Based on number of patients
*** Source: Company Reported / Evaluate Pharma

Biosimilar to Humira® (adalimumab)

- Branded Humira® market size in the United States (2021 net sales): $17.3 billion[1]
- Potential to be the first high-concentration interchangeable adalimumab in the United States
- FDA anticipated decision date on Alvotech's license application is April 13, 2023[2]
- FDA anticipated reinspection of Alvotech's manufacturing facility is scheduled for March 6, 2023[3]
- We are working towards our expected launch date of July 1, 2023, subject to FDA approval
- 2023 revenues of biosimilar to Humira® (adalimumab) are included in our 2023 outlook on a risk adjusted basis

References:
1. https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2021-financial;
2. https://investors.alvotech.com/news-releases/news-release-details/update-us-regulatory-status-avt02-alvotechs-proposed-high;
3. https://www.marketscreener.com/quote/stock/ALVOTECH-139628530/news/Alvotech-FDA-Inspection-of-Manufacturing-Facility-Form-6-K-42752643/;

ESG is Everyone's Business at Teva



Established Improved 2027 Long-Term Financial Targets

To be achieved by year - end 2027

Operating income margin[1][2]	Net debt/Adjusted EBITDA[2]	Cash-to-earnings[2][3][4]	Revenue growth[5]
30%	2.0X	80%	

Committed to utilizing cash flow to pay down debt; we do not plan to raise equity

1. Operating income margin = Non-GAAP operating income divided by net revenues.
2. All measures including operating income, Adjusted EBITDA and cash-to-earnings are presented on a non-GAAP basis.
3. Cash-to-earnings reflects free cash flow divided by non-GAAP net income attributable to ordinary shareholders.
4. Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets, net of cash used for capital investment.
5. Mid-single digit revenue CAGR on a constant currency basis.

Eli Kalif

EVP and Chief Financial Officer

Q4 2022 Summary

$ millions, except EPS	Q4 2022	Q4 2021	Q4 2022	Q4 2021
	GAAP		Non-GAAP	
Revenues*	3,884	4,100	3,884	4,100
Operating income (loss)	(855)	78	1,130	1,248
Net income (loss) attributable to Teva	(1,221)	(159)	791	854
Earnings (loss) per share ($)**	(1.10)	(0.14)	0.71	0.77
	1,111 million shares	1,103 million shares	1,121 million shares	1,108 million shares

* Revenues are presented on a GAAP basis
** Earnings per share based on a fully diluted basis

Non-GAAP Adjustments

$ millions	Q4 2022	Comments
Goodwill impairment charge	1,300	Mainly related to exchange rate fluctuations in International Markets and updated projections in our Teva API business
Amortization	156	
Impairment of long-lived assets	145	
Contingent consideration	63	
Accelerated depreciation	39	
Equity compensation	36	
Legal settlements and loss contingencies	34	Mainly related to an update of the opioids settlement provision
Restructuring costs	30	
Financial expenses	14	
Other	196	Including idle capacity, accelerated depreciation, write-offs and legal fees
Divested gain	(15)	
Non-controlling interests	(43)	
Corresponding tax effect	56	
Total adjustments	**2,012**	

Q4 2022 Non-GAAP Summary

$ billions, except EPS	Q4 2022	Q4 2021	Change	FY 2022	FY 2021	Change
Revenues*	3.9	4.1	(5%)	14.9	15.9	(6%)
Gross profit	2.1	2.3	(9%)	8.1	8.6	(6%)
	54.2%	*56.1%*	*(1.9%)*	*54.0%*	*54.2%*	*(0.3%)*
Operating income	1.1	1.2	(9%)	4.1	4.4	(6%)
	29.1%	*30.4%*	*(1.4%)*	*27.7%*	*27.7%*	*0.1%*
Adjusted EBITDA	1.2	1.4	(10%)	4.6	4.9	(6%)
Net income attributable to Teva	0.8	0.9	(7%)	2.8	2.9	(1%)
EPS ($)	0.71	0.77	(0.06)	2.52	2.58	(0.06)
	1,121 million shares	1,108 million shares		1,115 million shares	1,107 million shares	
Free cash flow**	**1.14**	**0.72**	**59%**	**2.24**	**2.20**	**2%**


* Revenues are presented on a GAAP basis


** FY 2021 Actual results include revenues from generic products in Japan divested on February 1st, 2021, along with a manufacturing site.

*** Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets, net of cash used for capital investment.

Spend Base

$ millions






Revenues	3,884	4,100	14,925	15,878
GP%	54.2%	56.1%	54.0%	54.2%
OP%	29.1%	30.4%	27.7%	27.7%


Operating Margin Expansion

Non-GAAP operating margin %




Free Cash Flow by Quarters

$ millions



Ongoing Debt Reduction


$ billions



	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022
Net Debt / EBITDAMAT*	4.25	4.29	4.16	4.02	4.00
Leverage	67%	69%	69%	69%	71%


*Teva's Net Debt/EBITDA MAT covenant ratio limits are 4.5x for Q1 2022 - Q3 2022 and 4.25x for Q4 2022

Net Debt Development




Debt Maturities

$ billions



Cash-to-Earnings

$ millions



Free Cash Flow

Cash-to-earnings*

Non-GAAP Net Income

* Free Cash Flow / non-GAAP Net income

2023 Non-GAAP Outlook

$ billions, except EPS or as noted	2023 Outlook	2022 Actual
Revenues*	**$14.8 – $15.4**	**$14.9**
COPAXONE ($m)*	~500	691
AUSTEDO ($m)*	~1,200	971
AJOVY ($m)*	~400	377
Operating Income	**4.0 – 4.4**	**4.1**
Adjusted EBITDA	**4.5 – 4.9**	**4.6**
Finance Expenses ($m)	~1,000	904
Tax Rate	14% – 17%	11.7%
Diluted EPS ($)	**2.25 – 2.55** 1,123 million shares	**2.52** 1,115 million shares
Free Cash Flow**	**1.7 – 2.1**	**2.2**
CAPEX*	0.5	0.5
Foreign Exchange	Volatile swings in FX can negatively impact revenue and income	

* Revenues and CAPEX are presented on a GAAP basis

** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables

In Summary

- Solid Q4 and full year 2022, on the backdrop of significant FX and macroeconomic headwinds
- AUSTEDO and AJOVY continue to drive growth
- Strong performance in Europe and International Markets
- Progress in our innovative medicine pipeline
- We remain committed to our long-term financial goals
- Looking forward to continuing our dialogue and sharing our strategy update mid-year


Q&A

Additional Information

FY 2022 Summary

$ millions, except EPS	FY 2022	FY 2021	FY 2022	FY 2021
	GAAP		Non-GAAP	
Revenues(*)(**)	14,925	15,878	14,925	15,878
Operating income (loss)	(2,099)	1,716	4,139	4,401
Net income (loss) attributable to Teva	(2,353)	417	2,812	2,855
Earnings (loss) per share ($)***	(2.12)	0.38	2.52	2.58
	1,110 million shares	1,107 million shares	1,115 million shares	1,107 million shares

* Revenues are presented on a GAAP basis

** 2021 Actual results include revenues from generic products in Japan divested on February 1st, 2021, along with a manufacturing site.

*** Diluted earnings per share based on diluted number of shares.

Quarterly GAAP Income Statement

$ millions, except EPS	Q4 2022	Q4 2022 Margins	Q4 2021	Q4 2021 Margins	Change
Revenues	**3,884**		**4,100**		**(5%)**
COGS	2,113	54.4%	2,049	50.0%	3%
Gross profit	**1,770**	**45.6%**	**2,050**	**50.0%**	**(14%)**
R&D	210	5.4%	244	5.9%	(14%)
S&M	549	14.1%	632	15.4%	(13%)
G&A	289	7.4%	276	6.7%	4%
Legal settlements and loss contingencies	34	0.9%	604	14.7%	(94%)
Impairments, restructuring and others	1,564	40.3%	242	5.9%	N/A
Other income	(19)	(0.5%)	(26)	(0.6%)	(26%)
Operating income (loss)	**(855)**	**(22.0%)**	**78**	**1.9%**	**N/A**
Financial expenses, net	245	6.3%	253	6.2%	(3%)
Tax	154	(14.0%)*	(24)	13.9%*	*N/A*
Minority and share in profit	(33)	(0.8%)	8	0.2%	*N/A*
Net income (loss) attributable to Teva	**(1,221)**	**(31.4%)**	**(159)**	**(3.9%)**	**N/A**
# of shares (diluted, millions)	1,111		1,103		
Earnings per share ($)	**(1.10)**		**(0.14)**		

* Represents taxrate

FY 2022 GAAP Income Statement

$ millions, except EPS	FY 2022	FY 2022 Margins	FY 2021	FY 2021 Margins	Change
Revenues	**14,925**		**15,878**		**(6%)**
COGS	7,952	53.3%	8,284	52.2%	(4%)
Gross profit	**6,973**	**46.7%**	**7,594**	**47.8%**	**(8%)**
R&D	838	5.6%	967	6.1%	(13%)
S&M	2,265	15.2%	2,429	15.3%	(7%)
G&A	1,180	7.9%	1,099	6.9%	7%
Legal settlements and loss contingencies	2,082	13.9%	717	4.5%	N/A
Impairments, restructuring and others	2,814	18.9%	765	4.8%	N/A
Other income	(107)	(0.7%)	(98)	(0.6%)	9%
Operating income (loss)	**(2,099)**	**(14.1%)**	**1,716**	**10.8%**	**N/A**
Financial expenses, net	966	6.5%	1,058	6.7%	(9%)
Tax	(638)	20.8%*	211	32.0%*	*N/A*
Minority and share in profit (loss)	(74)	(0.5%)	30	0.2%	*N/A*
Net income (loss) attributable to Teva	**(2,353)**	**(15.8%)**	**417**	**2.6%**	**N/A**
# of shares (diluted, millions)	1,110		1,107		
Earnings (loss) per share ($)	**(2.12)**		**0.38**		


* Represents taxrate

Q4 2022 Foreign Exchange Impact

$ millions	Q4 2022	Q4 2021	Diff	FX Effect	Diff net FX
Revenues	3,884	4,100	(216)	(270)	54
Operating income **GAAP**	(855)	78	(933)	(132)	(801)
Operating income **Non-GAAP**	1,130	1,248	(118)	(135)	16

Net Revenue and Non-GAAP Profitability

$ millions




Revenues by Activity and Geographical Area

$ millions	Q4-21	Q1-22	Q2-22	Q3-22	Q4-22	FY21	FY22
North America Segment	**2,003**	**1,737**	**1,904**	**1,809**	**2,002**	**7,809**	**7,452**
Generic products	905	899	1,026	806	818	3,769	3,549
AJOVY®	53	36	49	57	75	176	218
AUSTEDO®	282	154	204	260	344	802	963
BENDEKA®/TREANDA®	93	82	83	77	75	385	316
COPAXONE®	129	86	94	105	101	577	387
Anda	355	342	308	371	450	1,323	1,471
Other	186	139	139	133	138	777	549
Europe Segment	**1,268**	**1,156**	**1,171**	**1,069**	**1,129**	**4,886**	**4,525**
Generic products	932	876	873	803	914	3,569	3,466
AJOVY®	29	30	29	30	35	87	124
COPAXONE®	95	72	72	63	61	391	268
Respiratory	93	71	65	62	75	356	273
Other	119	107	131	111	43	483	392
International Markets Segment	**527**	**492**	**454**	**475**	**482**	**2,032**	**1,903**
Generic products	438	388	394	393	411	1,649	1,586
AJOVY®	4	6	10	6	13	50	35
COPAXONE®	8	10	9	9	7	37	36
Other	77	88	40	67	51	295	246
Other	**302**	**275**	**257**	**241**	**272**	**1,151**	**1,045**
Total Teva	**4,100**	**3,661**	**3,786**	**3,595**	**3,884**	**15,878**	**14,925**


Non-GAAP Profits and EPS

$ millions, EPS in $




Q4 2022 Non-GAAP Operating Income

$ millions




FY 2022 Non-GAAP Operating Income

$ millions



Quarterly Non-GAAP Operating Income




Revenues:	**4,100**	**3,661**	**3,786**	**3,595**	**3,884**

Numbers in brackets present a percentage of the total figure

Quarterly Adjusted EBITDA*


$ millions



Please see our press release reporting our financial results for the fourth quarter of 2022 and the year ended December 31, 2022 for a reconciliation of Adjusted EBITDA to its nearest GAAP equivalent

Q4 2022 Adjusted EBITDA to Free Cash Flow


$ millions



* Q4 securitization cash flow net impact +837m

FY 2022 Adjusted EBITDA to Free Cash Flow

$ millions




* FY-22 securitization cash flow net impact +794m

Consolidated Balance Sheet

$ billions	Dec 31, 2022	Dec 31, 2021	Diff
Cash and Cash Equivalents	2.8	2.2	0.6
AR Trade	3.7	4.5	(0.8)
Pre-paid Expenses and Other Current Assets	1.7	2.1	(0.3)
Inventory	3.8	3.8	0.0
Fixed Assets	5.7	6.0	(0.2)
Intangible Assets	6.3	7.5	(1.2)
Goodwill	17.6	20.0	(2.4)
Other Long Term Assets	2.3	1.6	0.7
Total Assets	**44.0**	**47.7**	**(3.7)**
AP Trade	1.9	1.7	0.2
SR&A	3.8	4.2	(0.5)
AP Other	3.7	3.7	0.0
Total Debt (ST+LT)	21.2	23.0	(1.8)
Other Long Term liabilities	4.7	3.8	1.0
Minority	0.8	1.0	(0.2)
Teva Shareholders' Equity	7.9	10.3	(2.4)
Total Liabilities & Equity	**44.0**	**47.7**	**(3.7)**


Q4 2022 Debt Movements

$ Billions



FY 2022 Debt Movements

$ Billions




teva